Summary Escalating health care costs have made it imperative to evaluate the resources required to diagnose and treat major illnesses in Canadians. For Canadian men, lung cancer is not only the most common malignancy, but also the major cancer killer. As of 1994. lung cancer is expected to overtake breast cancer as the leading cause of cancer deaths in women. This paper presents a detailed description of the methodology used to determine the direct health care costs associated with 'standard' diagnostic and therapeutic approaches for lung cancer Lung cancer is the most common malignancy in Canada. For Canadian men, it is associated with the highest rates of both cancer-related incidence and mortality (National Cancer Institute of Canada, 1992) , and it is expected to overtake breast cancer in 1994 as the leading cause of cancer deaths in women (National Cancer Institute of Canada, 1994). Because it is a major health care problem in Canada, it was thought useful to develop a model of the management of lung cancer, and to identify the individual cost components associated with diagnosis, treatment and terminal care. This paper describes the model and summarises some of the principal costs of lung cancer management.
Lung cancer is the most common malignancy in Canada. For Canadian men, it is associated with the highest rates of both cancer-related incidence and mortality (National Cancer Institute of Canada, 1992) , and it is expected to overtake breast cancer in 1994 as the leading cause of cancer deaths in women (National Cancer Institute of Canada, 1994) . Because it is a major health care problem in Canada, it was thought useful to develop a model of the management of lung cancer, and to identify the individual cost components associated with diagnosis, treatment and terminal care. This paper describes the model and summarises some of the principal costs of lung cancer management.
As the choice of therapy for lung cancer is determined by the histological cell type (small-cell or non-small-cell) and the extent of disease at diagnosis (tumour stage) (Skarin. 1993) , the model includes algorithms for diagnosis and staging according to the two main histological cell types: small-cell and non-small-cell lung cancer. The model also incorporates treatment algorithms that include surgery, radiation therapy, chemotherapy or combinations of these modalities appropriate for tumour type and stage (Shields, 1992 (Evans et al., 1987; Rapp et al., 1988 during the diagnostic work-up phase of some patients, when more than one specialist is involved. The continuing involvement of the family physician in the care of the patient following the diagnosis of cancer is not costed because of its variability.
The costs associated with the procedures, tests and fees included in the diagnostic module are shown in Table I . The most commonly used preoperative investigations are assumed to be a surgical consultation, ECG, pulmonary function studies and arterial blood gases. It is assumed that all patients undergo these investigations to determine operability. It is also asumed that all surgical candidates undergo bronchoscopy and cervical mediastinoscopy. The proportion of patients having preoperative CT scans of the chest is unknown, and practice varies according to the availability of CT scanners, the preference of the thoracic surgeon or respirologist and the size and location of the primary tumour. Certainly, with the increasing availability of CT scanners, the proportion of patients undergoing this procedure preoperatively is increasing. We, therefore, undertook sensitivity analyses around the percentage of patients having CT scans ranging from 50 to 100%.
Therapeutic approaches for non-small-cell lung cancer Stage I and II The treatment algorithm for the management of patients with stage I or II NSCLC is shown in Figure 1 . Based on data from the Ontario Cancer Registry, 88% of surgially managed patients are treated by lobectomy or other lung-preserving surgical procedure (segmental resection or wedge resection). Twelve percent of stage I and H patients require a pneumonectomy. The cost of surgery includes the surgical procedure, assistant and anaesthetist fees, pathology consultation and pathology laboratory technical fees.
The Ontario Cancer Registry provided data on the average duration of hospitalisation for newly diagnosed lung cancer patients who underwent surgical resection in 1984. It was surprising to note that this averaged 20 days in 1984. This period of hospitalisation was inclusive of the post-operative recovery period, as well as any in-hospital consultations, diagnostic tests or staging procedures. Twenty days of hospitalisation was used in the model, although data for 1988 and 1990 show a small decline (2 days) in the average length of stay for initial hospitalisation. Information obtained from our survey of thoracic surgeons imdicated that the usual post-operative recovery period is 6-8 days depending on the type of operative procedure. Presumably, the difference (12-14 days) can be attributed to the diagnostic and staging work-up or waiting on tests, consults or procedures to be booked.
In order to estimate the proportion of patients who would be partially or completely resected, and those who would be referred for radiotherapy, a questionnaire survey was sent to 25 thoracic surgeons in Canada. All 25 questionnaires were completed and returned and the average of their responses was used to estimate the proportion of patients treated at (Kristjansen, 1989) . (Statistics Canada. 1991 
